AstraZeneca PLC, Datopotamab Deruxtecan (Dato-DXd) - (TROPION · Metastatic triple negative breast cancer (TNBC).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/5/25) through T+5. Run-up high $209.48 on 2/18/26, low $179.64 on 12/16/25 (T-120 to T-1). FDA decision 5/22/26. Historical price action, not a forecast.
Drug / candidateDatopotamab Deruxtecan (Dato-DXd) - (TROPION
CompanyAstraZeneca PLC
120-day run-up (T-120→T-1)+2.3%
Questions
Was Datopotamab Deruxtecan (Dato-DXd) - (TROPION approved by the FDA?
Yes. The FDA approved the application for Datopotamab Deruxtecan (Dato-DXd) - (TROPION on May 22, 2026. The primary source is linked on this page.
Which company is behind Datopotamab Deruxtecan (Dato-DXd) - (TROPION?
Datopotamab Deruxtecan (Dato-DXd) - (TROPION is a AstraZeneca PLC (AZN) program. The FDA decision came on May 22, 2026; the company's own announcement is linked on this page.
How did AZN stock trade into the FDA decision?
Measured over the 120 trading days before the decision (T-120 to T-1), AZN moved +2.3%. That is the recorded price path into this specific event -- historical measurement, not a prediction, and not investment advice.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.